OrbiMed Advisors CGON Position
Active13-Fund ConvergenceOrbiMed Advisors trimmed their position in CG Oncology, Inc. (CGON) in Q4 2025, holding $63.0M worth of shares across 1,516,550 shares.
The position was first reported in Q3 2024 and has been tracked across 6 quarterly 13F filings.
CGON is a convergence signal: 13 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for Ivaltinostat in 75 days (Jun 30, 2026), making the timing of OrbiMed's position particularly relevant.
Short interest stands at 13.2% of float with 8.6 days to cover, indicating significant bearish positioning against OrbiMed's long thesis.
About CG Oncology, Inc.
CG Oncology Inc is a clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. Their product candidate cretostimogene, is initially in clinical development for the treatment of patients with high-risk Non-Muscle Invasive Bladder Cancer who are unresponsive to Bacillus Calmette Guerin (BCG) therapy, the current standard-of-care for high-risk NMIBC.
Full company profile →Short Interest
13.2%
8.6 days to cover
OrbiMed Advisors CGON Position History
Frequently Asked Questions
Does OrbiMed Advisors own CGON?
Yes. As of Q4 2025, OrbiMed Advisors holds 1,516,550 shares of CG Oncology, Inc. (CGON) valued at $63.0M. This data comes from their SEC 13F filing.
How many hedge funds own CGON?
13 specialist biotech hedge funds currently hold CGON, including RTW Investments, BVF Partners, RA Capital Management and 9 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did OrbiMed Advisors first buy CGON?
OrbiMed Advisors's position in CGON was first reported in Q3 2024. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is OrbiMed Advisors's CGON position increasing or decreasing?
OrbiMed Advisors trimmed their CGON position in the most recent quarter, reducing by 210,300 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
CGONCompany Page →
All fund holders, insider trades, catalysts, and cash runway
OrbiMed AdvisorsPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →